|Cellartis||Y00275||Cellartis® human iPS cell line 7 (ChiPSC7) Kit||1 Kit||￥22,525|
|Cellartis||Y00285||Cellartis® human iPS cell line 12 (ChiPSC12) Kit||1 kit||￥22,525|
|Cellartis||Y00315||Cellartis® human iPS cell line 21 (ChiPSC21) Kit||1 Kit||￥22,525|
|Cellartis||Y00325||Cellartis® human iPS cell line 22 (ChiPSC22) Kit||1 kit||￥22,525|
|Cellartis||Y00305||Cellartis® human iPS cell line 18 (ChiPSC18) Kit||1 Kit||￥22,525|
(Human Induced Pluripotent Stem Cells)
|Characteristics of Cellartis human iPS cells. The cell lines were generated from fibroblasts using defective polycistronic retrovirus technology to deliver Oct-4, Sox-2, KLF-4, and c-Myc. The skin fibroblasts were obtained from donors of varying age and gender, have a normal karyotype, and have been confirmed to differentiate into specific cell lineages. Consent was obtained from all donors for commercial use.|
|1. de Peppo GM, et al. Osteogenic potential of human mesenchymal stem cells and human embryonic stem cell-derived mesodermal progenitors: a tissue engineering perspective. Tissue Eng Part A.2010 Nov;16(11):3413-3426.
2. Both SK, et al. Differential bone-forming capacity of osteogenic cells from either embryonic stem cells or bone marrow-derived mesenchymal stem cells. J Tissue Eng Regen Med.2011 Mar;5(3):180-190.
3. de Peppo GM, et al. Free-form-fabricated commercially pure Ti and Ti6A14V Porous Scaffolds support the growth of human embryonic stem cell-derived mesodermal progenitors. ScientificWorldJournal. 2012;2012:646417.Epub 2012 Jan 4.
4. Ou Li, et al. Human embryonic stem cell-derived mesenchymal stroma cells(hES-MSCs) engraft in vivo and support hematopoiesis without suppression immune function: implications for off –the shelf ES-MSC therapies. PLOS ONE.2013; 8(1):e55319.